UB274
ProductPiperacillin Sodium and Tazobactam Sodium for Injection
Strength0.5g: 0.125g; 1.0g: 0.25g; 2.0g: 0.5g; 0.5g: 0.0625g; 1.0g: 0.125g; 2.0g: 0.25g; 3.0g; 0.375g; 4.0g: 0.5g
IndicationsAppendicitis; Peritonitis; Skin infection; Soft tissue infection; Cellulitis; Skin abscess; Foot infection; Endometritis; Pelvic inflammatory disease; Community acquired pneumonia; Nosocomial pneumonia; Bacterial infection
TherapeuticsInfectious Diseases
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule
Exclusive Summary
- - Core patents expired years ago with widespread generics, enabling fast distribution entry and tender participation.
- - Addresses high-burden infections (cIAI, HAP/VAP, sepsis) with large, steady hospital demand.
- - Listed on the WHO EML and recommended by major guidelines as first-line/empiric therapy, supporting carbapenem-sparing strategies.
- - Although competition is crowded, recurrent supply shortages create room for reliable, full-portfolio suppliers to win tenders and substitutions.
- - Typically delivers 60–90% savings versus originator, fitting both GPO-driven and price-sensitive emerging markets.
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →